Pathogenic B-T Cell Axis Driven by BAFF Induces Endothelial Apoptosis in SLE-PAH
- 23 October 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (10)
Abstract
BACKGROUND: Pulmonary arterial hypertension (PAH) is a fatal complication of systemic lupus erythematosus (SLE), yet the mechanisms linking autoimmune dysregulation to progressive pulmonary vascular remodeling are poorly defined, leading to inadequate therapies. This study investigated BAFF (B-cell activating factor), a key cytokine in SLE, as a potential driver of SLE-PAH pathogenesis. METHODS: BAFF expression was assessed in patients with SLE-PAH and animal models. Humanized BAFF-transgenic mice were generated to investigate the effects of BAFF elevation on serological, hemodynamic, and histological parameters of SLE and PAH. Single-cell RNA sequencing, flow cytometry, histological analyses, and cell-based experiments were performed to elucidate cellular and molecular mechanisms. The therapeutic efficacy of the BAFF-neutralizing antibody Belimumab was tested in 2 distinct SLE-PAH animal models. RESULTS: BAFF was significantly upregulated in both SLE-PAH patient cohorts and animal models. Humanized BAFF-transgenic mice exhibited systemic B-cell hyperactivation and pulmonary infiltration and spontaneously developed hallmark features of both SLE and PAH. Single-cell transcriptomic analysis of lung tissues revealed that BAFF overexpression drove the increase of a novel, disease-specific S 100a6 + mature B-cell subset, which orchestrated a pathogenic immune cascade by activating a cytotoxic Gzmk + CD8 + T-cell population via MHC-I (major histocompatibility complex class I)-mediated antigen presentation and CD80-CD28 costimulation. This B-T cell crosstalk triggered apoptosis of a susceptible endothelial cell subpopulation through Fas/Fas ligand signaling, ultimately culminating in pulmonary vascular remodeling. The BAFF-neutralizing antibody Belimumab effectively ameliorated both autoimmune and cardiopulmonary manifestations in 2 distinct SLE-PAH animal models, while improving survival. CONCLUSIONS: These findings establish BAFF as a key mediator in SLE-PAH, driving a previously unrecognized pathogenic immune axis connecting dysregulated B cells to T-cell-mediated endothelial injury. BAFF inhibition may represent a therapeutic strategy for SLE-PAH.Keywords
This publication has 77 references indexed in Scilit:
- Activin A–Activated ALK4 Induces Pathogenic Th17‐Involved Endothelial–Mesenchymal Transition in Systemic Lupus Erythematosus–Associated Pulmonary Arterial HypertensionArthritis & Rheumatology, 2025
- Increased Expression of CD74 in Atherosclerosis Associated with Inflammatory Responses of Endothelial Cells and MacrophagesBiochemical Genetics, 2023
- Multiparametric Flow Cytometry Analysis of Naïve, Memory, and Effector T Cells2019
- Porphyromonas gingivalis-Induced MIF Regulates Intercellular Adhesion Molecule-1 Expression in EA.hy926 Cells and Monocyte-Endothelial Cell Adhesion Through the Receptors CD74 and CXCR4Inflammation, 2018
- Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: A PRISMA-compliant systematic review and meta-analysisAutoimmunity Reviews, 2016
- Epicutaneous Application of Toll‐like Receptor 7 Agonists Leads to Systemic Autoimmunity in Wild‐Type Mice: A New Model of Systemic Lupus ErythematosusArthritis & Rheumatology, 2013
- Elevated Serum BAFF Levels Are Associated With Rising Anti–Double‐Stranded DNA Antibody Levels and Disease Flare Following B Cell Depletion Therapy in Systemic Lupus ErythematosusArthritis & Rheumatism, 2013
- Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosusArthritis & Rheumatism, 2012
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusArthritis & Rheumatism, 2011
- Mutation of the BAFF furin cleavage site impairs B‐cell homeostasis and antibody responsesEuropean Journal of Immunology, 2010